STOCK TITAN

EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

EDAP TMS SA (NASDAQ: EDAP), a global leader in robotic energy-based therapies, has scheduled its first quarter 2025 financial results announcement for May 15, 2025, before market open. The company will host a conference call and webcast at 8:30 AM EDT on the same day.

The earnings discussion will be led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch. Investors can join via phone using the domestic line (1-800-267-6316) or international line (1-203-518-9783) with passcode "EDAP", or through the webcast platform.

EDAP TMS SA (NASDAQ: EDAP), leader mondiale nelle terapie robotiche basate sull'energia, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 15 maggio 2025, prima dell'apertura dei mercati. La società terrà una conference call e una webcast alle 8:30 AM EDT dello stesso giorno.

La discussione sui risultati sarà guidata dal CEO Ryan Rhodes, dal CFO Ken Mobeck e dal Chief Accounting Officer François Dietsch. Gli investitori potranno partecipare telefonicamente utilizzando la linea nazionale (1-800-267-6316) o la linea internazionale (1-203-518-9783) con il codice d'accesso "EDAP", oppure tramite la piattaforma webcast.

EDAP TMS SA (NASDAQ: EDAP), líder global en terapias robóticas basadas en energía, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 15 de mayo de 2025, antes de la apertura del mercado. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:30 AM EDT del mismo día.

La discusión de los resultados estará a cargo del CEO Ryan Rhodes, el CFO Ken Mobeck y el Director de Contabilidad François Dietsch. Los inversores pueden unirse por teléfono usando la línea nacional (1-800-267-6316) o la línea internacional (1-203-518-9783) con el código de acceso "EDAP", o a través de la plataforma de transmisión en vivo.

EDAP TMS SA (NASDAQ: EDAP)는 에너지 기반 로봇 치료 분야의 글로벌 리더로서, 2025년 1분기 재무 결과 발표를 2025년 5월 15일 시장 개장 전으로 예정했습니다. 회사는 같은 날 오전 8시 30분 EDT에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.

실적 발표는 CEO 라이언 로즈, CFO 켄 모벡, 최고 회계 책임자 프랑수아 디에치가 주도할 예정입니다. 투자자들은 국내 전화선 (1-800-267-6316) 또는 국제 전화선 (1-203-518-9783)을 통해 암호 "EDAP"을 사용하거나 웹캐스트 플랫폼을 통해 참여할 수 있습니다.

EDAP TMS SA (NASDAQ : EDAP), leader mondial des thérapies robotiques à base d'énergie, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le 15 mai 2025, avant l'ouverture des marchés. La société organisera une conférence téléphonique et une webdiffusion à 8h30 EDT le même jour.

La présentation des résultats sera animée par le CEO Ryan Rhodes, le CFO Ken Mobeck et le Chief Accounting Officer François Dietsch. Les investisseurs pourront participer par téléphone en utilisant la ligne nationale (1-800-267-6316) ou la ligne internationale (1-203-518-9783) avec le code d'accès "EDAP", ou via la plateforme de webdiffusion.

EDAP TMS SA (NASDAQ: EDAP), ein weltweit führendes Unternehmen für robotergestützte, energiebasierte Therapien, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 15. Mai 2025 vor Börsenöffnung geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr EDT eine Telefonkonferenz und ein Webcast veranstalten.

Die Ergebnisbesprechung wird von CEO Ryan Rhodes, CFO Ken Mobeck und Chief Accounting Officer François Dietsch geleitet. Investoren können über die nationale Telefonnummer (1-800-267-6316) oder die internationale Nummer (1-203-518-9783) mit dem Zugangscode "EDAP" oder über die Webcast-Plattform teilnehmen.

Positive
  • None.
Negative
  • None.

Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT

LYON, France, May 1, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2025, before the markets open on Thursday, May 15th, 2025.

An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for conference call dial-in information and webcast registration.

Call Details:

Date:                Thursday, May 15th

Time:                 8:30 am EDT

Domestic:          1-800-267-6316

International:      1-203-518-9783

Passcode:         EDAP

Webcast:         https://viavid.webcasts.com/starthere.jsp?ei=1714475&tp_key=2c6b64f895

About EDAP TMS SA

A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.

Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com


FAQ

When will EDAP (NASDAQ: EDAP) report Q1 2025 earnings?

EDAP will report its Q1 2025 earnings before markets open on Thursday, May 15th, 2025.

How can I join EDAP's Q1 2025 earnings call?

Investors can join via phone (US: 1-800-267-6316, International: 1-203-518-9783, passcode: EDAP) or webcast at 8:30 AM EDT on May 15th, 2025.

Who will lead EDAP's Q1 2025 earnings call?

The call will be led by CEO Ryan Rhodes, CFO Ken Mobeck, and Chief Accounting Officer François Dietsch.

What is EDAP's main business focus?

EDAP TMS SA is the global leader in robotic energy-based therapies.
Edap Tms

NASDAQ:EDAP

EDAP Rankings

EDAP Latest News

EDAP Stock Data

79.27M
37.39M
41.47%
0.11%
Medical Distribution
Healthcare
Link
France
Lyon